Mohit Manrao, head of AstraZeneca’s US oncology business unit, explained the company’s diverse approach in an interview, including investments in ADCs, cell therapy and radiopharmaceuticals.

Funding for UK biotechs shrank again last year but sector leaders see hope of green shoots in 2024.

AstraZeneca has maintained sector-beating growth for five years, but is looking to a new wave of bolt-on acquisitions and licensing deals to sustain that trajectory beyond 2030.

Eisai and Lilly were the biggest winners at the 19^th Annual Scrip Awards in a glittering ceremony at the Dorchester in London’s Mayfair, hosted by the actor and comedian Jon Culshaw.